Central Nervous System Drugs Global Market Report 2018

Central Nervous System Global Market Report 2018 Including: Anaesthetics; Analgesics; Anti-Parkinson drugs; Anti-Epileptics; Other CNS drugs Covering: Biogen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novartis AG

Feb 2018

Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information.

• Identify growth segments for investment.

• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

• Create regional and country strategies on the basis of local data and analysis.

• Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors.

• Develop strategies based on likely future developments.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market.

• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Scope Markets Covered: Anaesthetics; Analgesics; Anti-Parkinson drugs; Anti-Epileptics; Other CNS drugs Companies Mentioned: Biogen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novartis AG Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Central Nervous System Indicators Comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Central Nervous System Market Characteristics The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.

Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.

The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

The central nervous system drugs market can be classified as follows – Analgesics relieves pain selectively without blocking the conduction of nerve impulses, noticeably changing sensory Anti-Parkinson Drugs are used to treat symptoms of Parkinson's disease and other forms of Parkinsonism which are caused Anesthetics cause unconsciousness and unresponsiveness to the body by suppressing responses to sensory stimulation in Anti-Epileptics Drugs (AED), also known as anticonvulsants, are preventative drugs used to control epileptic seizures, Other central nervous system drugs include the following: Antiemetics are the drugs used to relieve nausea and vomiting caused by a various medical conditions and situations such

Muscle Relaxants are a heterogeneous group of medications that affect skeletal muscle function to relieve muscle Sedatives are central nervous system (CNS) depressants that reduce normal brain functioning. These drugs modulate

In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

Central Nervous System Market Historic Growth The global central nervous system market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%.

The chart and table below shows the year-on-year growth of the global central nervous system market during 2013 – 2017.

Drivers of the Market:

Restraints on the Market:

Central Nervous System Market Forecast Growth The global Central Nervous System Drugs market grew from $XX billion in 2017 to $87.2 billion in 2021 at a compound annual growth rate (CAGR) of XX%. Going forward, the growth of this market can be attributed to steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions. The geriatric population and rise in diseases such as Parkinson’s, Alzheimer’s and other mental disorders is also likely to continue to drive the market for central nervous system drugs in the forecast period.

The chart and table below shows the year-on-year growth of the global central nervous system market during 2017 - 2021.

Drivers of the Market:

Restraints on the Market:

Central Nervous System Market Segmentation The chart and table below shows the split of the central nervous system market in 2017.

The total market value for central nervous system was $X billion in 2017. The markets that are covered include Anaesthetics; Analgesics; Anti-Parkinson drugs; Anti-Epileptics; Other CNS drugs.

Anaesthetics was the x largest segment in the central nervous system market with X% share of the market. The market value for the anaesthetics was $x billion in 2017.

Analgesics made up around X% share of the market. The market value for the analgesics was $x billion in 2017.

Central Nervous System Market Regional And Country Analysis The Asia Pacific was the x largest region in the central nervous system market in 2017, central nervous system for $X billion or X% market share.

North America was the x largest region central nervous system for $X billion or X% market share.

Europe was the x largest region central nervous system for $X billion or X% market share.

Central Nervous System Market Competitive Landscape The leading competitors in the global central nervous system market are Biogen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novartis AG The chart and table below displays the percentage market share of the top players in the central nervous system market industry.

Biogen Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

F. Hoffmann-La Roche Ltd. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

Shire Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

UCB S.A. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

Eli Lilly And Company generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

Sanofi S.A. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

Daiichi Sankyo Company, Limited generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

Company Profile Biogen Inc. Overview Biogen Idec was the X largest company in the central nervous system drugs market in 2017 with a XX% share of the market. The company was founded in 1978 and is headquartered in Massachusetts, USA. It is involved in discovering, developing, and selling medical products used to treat neurological disorders such as multiple sclerosis, and inflammatory diseases

such as rheumatoid arthritis. Biogen Idec has offices in Australia, the Brazil, Japan, India, and China.

Products and Services Biogen Idec operates through following divisions – The Research And Development Organization division is engaged in the research and discovery of new therapy products and supports development and The Pharmaceutical, Operations And Technology Organization division is involved in the development of the manufacturing processes, clinical trial supply, The Commercial Organization division manages the development of the company’s products Strategy Biogen Idec’s growth strategy is to develop and expanding its neurology portfolio. In this regard, the company acquired UK-based clinical-stage biopharmaceutical company Convergence Pharmaceuticals, in January 2015.

Convergence Financial Performance Biogen’s Multiple Sclerosis drugs in Pharmaceutical, Operations And Technology Organization division, involved in central nervous system drugs manufacturing, generated revenues of $XX billion for the financial year 2016, a XX% decrease from

F. Hoffmann-La Roche Ltd Overview Products and Services Strategy Financial Performance

Johnson & Johnson Overview Products and Services Strategy Financial Performance

Pfizer Inc. Overview Products and Services Strategy Financial Performance

Novartis AG Overview Products and Services Strategy Financial Performance